Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CohBar, Inc. stock logo
CWBR
CohBar
$0.41
$0.41
$0.00
$1.01
$1.19M1.394,364 shsN/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$0.01
$0.01
$0.01
$0.02
$1.19M-0.92435,993 shs39,482 shs
Oragenics, Inc. stock logo
OGEN
Oragenics
$1.51
+4.5%
$4.56
$1.35
$75.60
$1.24M0.95188,276 shs2.00 million shs
TRPXD
Therapix Biosciences
$0.00
$2.75
$22.40
$299KN/A1,852 shs900 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CohBar, Inc. stock logo
CWBR
CohBar
0.00%0.00%0.00%0.00%-18.00%
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.00%+6.38%+6.38%+3.09%+4.71%
Oragenics, Inc. stock logo
OGEN
Oragenics
0.00%-62.84%-59.32%-73.20%-95.13%
TRPXD
Therapix Biosciences
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CohBar, Inc. stock logo
CWBR
CohBar
N/AN/AN/AN/AN/AN/AN/AN/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.861 of 5 stars
0.03.00.04.80.00.00.0
Oragenics, Inc. stock logo
OGEN
Oragenics
0.2275 of 5 stars
0.02.00.00.02.80.00.0
TRPXD
Therapix Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CohBar, Inc. stock logo
CWBR
CohBar
0.00
N/AN/AN/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.00
N/AN/AN/A
Oragenics, Inc. stock logo
OGEN
Oragenics
0.00
N/AN/AN/A
TRPXD
Therapix Biosciences
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CohBar, Inc. stock logo
CWBR
CohBar
N/AN/AN/AN/A$5.27 per shareN/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$11.39M0.10N/AN/A($2.64) per share0.00
Oragenics, Inc. stock logo
OGEN
Oragenics
N/AN/AN/AN/A$0.61 per shareN/A
TRPXD
Therapix Biosciences
N/AN/AN/AN/A$0.28 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CohBar, Inc. stock logo
CWBR
CohBar
-$12.18MN/A0.00N/AN/AN/AN/AN/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$52.98M-$0.05N/AN/A-46.42%-91.97%-61.93%N/A
Oragenics, Inc. stock logo
OGEN
Oragenics
-$20.66M-$33.63N/AN/AN/A-2,087.95%-486.56%N/A
TRPXD
Therapix Biosciences
-$4.79MN/A0.00N/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CohBar, Inc. stock logo
CWBR
CohBar
N/AN/AN/AN/AN/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/AN/AN/AN/AN/A
Oragenics, Inc. stock logo
OGEN
Oragenics
N/AN/AN/AN/AN/A
TRPXD
Therapix Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CohBar, Inc. stock logo
CWBR
CohBar
N/AN/AN/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/A
0.11
0.09
Oragenics, Inc. stock logo
OGEN
Oragenics
N/A
1.93
1.93
TRPXD
Therapix Biosciences
N/A
0.49
N/A

Institutional Ownership

CompanyInstitutional Ownership
CohBar, Inc. stock logo
CWBR
CohBar
2.47%
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.22%
Oragenics, Inc. stock logo
OGEN
Oragenics
18.71%
TRPXD
Therapix Biosciences
14.32%

Insider Ownership

CompanyInsider Ownership
CohBar, Inc. stock logo
CWBR
CohBar
6.51%
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.21%
Oragenics, Inc. stock logo
OGEN
Oragenics
4.90%
TRPXD
Therapix Biosciences
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
CohBar, Inc. stock logo
CWBR
CohBar
102.91 millionN/ANot Optionable
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
120118.66 million113.12 millionNot Optionable
Oragenics, Inc. stock logo
OGEN
Oragenics
5823,00010.98 millionN/A
TRPXD
Therapix Biosciences
850,000N/ANot Optionable

Recent News About These Companies

TRON (CRYPTO: TRX)
Paddle Healthy: TRX Workout
Dead: RAM 1500 TRX
2024 Ram 1500 TRX Final Edition Brings the End
T. Rowe Price Retirement I 2040 I
2022 Ram 1500 TRX

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
CohBar stock logo

CohBar NASDAQ:CWBR

$0.41 0.00 (0.00%)
As of 01/23/2025

CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.

Evofem Biosciences stock logo

Evofem Biosciences NASDAQ:EVFM

$0.01 0.00 (0.00%)
As of 07/3/2025 11:39 AM Eastern

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Oragenics stock logo

Oragenics NYSE:OGEN

$1.50 +0.07 (+4.51%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$1.54 +0.04 (+2.66%)
As of 07/3/2025 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

Therapix Biosciences OTCMKTS:TRPXD

Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include THX-110, which has completed Phase II a clinical trial for the treatment of Tourette syndrome and Obstructive Sleep Apnea; THX-160, which has completed two preliminary preclinical studies for the treatment of acute and chronic pain; and THX-210 for the treatment of autism spectrum disorder and epilepsy. The company was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013. Therapix Biosciences Ltd. was founded in 2004 and is headquartered in Givatayim, Israel.